BioSpace News Archive

Olympus Surveys Patient Perceptions on Colorectal Cancer and Other Minimally Invasive Procedures

Multiple Human Clinical Trials Have Demonstrated Unprecedented Success in Cancers, Including HCC Liver Cancer, Vascular and Other Diseases, and Viruses

PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform designed to provide more effective and safer products, today announced the pricing of an underwritten public offering of 7,875,000 shares of its common stock,

Ceapro Inc.(TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that Gilles Gagnon, President and Chief Executive Officer of Ceapro will present at the virtual H.C. Wainwright Global Life Sciences Conference taking place March 9-10, 2021.

BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced today that the company has formed a community of periodontists through the development of the Waterlase Perio Academy (WPA)

Pharmaceutical Associates, Inc. (PAI) today announced the appointment of Brandon Rockwell as Chief Operating Officer, bringing 15 years of business development experience to the company.

PMC Regional Hospital, a physician-owned hospital based in New Albany, Indiana, today announced that it is the first hospital in the Kentuckiana area to offer enlarged prostate and kidney stone procedures with the MOSES 2.0 Pulse 120H holmium laser.

Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, announced today that its Chief Executive Officer, Mr James Nathanielsz, provides a shareholder update for 2021 as business confidence increases,

Nu-Tek BioSciences, LLC, an innovative manufacturer of industrial ingredients used in the development and manufacturing of pharmaceuticals, announced today that the company will build a new manufacturing facility in Austin, Minnesota.

Genomma Lab Internacional, S.A.B. de C.V., one of the leading pharmaceutical and personal care product companies in Mexico with an expanding international presence, announces its 2025 Sustainability Strategy, underscoring the importance of sustainability in fulfilling the Company’s mandate of delivering transformational products which empower customers to thrive through optimal health and well-being.